20 articles
Comprehensive review reveals autoimmune markers present before symptoms and highlights automated insulin delivery breakthroughs.
New research reveals how a single antibody treatment creates lasting protection against autoimmune diabetes by reshaping immune cells.
Monitoring IgG protein levels during first year of treatment can predict which patients will experience disease relapse.
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
A randomized trial shows prophylactic obinutuzumab dramatically reduces steroid-requiring cGVHD after bone marrow transplant.
Researchers tested whether eosinophil ฮฒ1 integrin activation in blood could track disease activity, potentially sparing patients repeat invasive procedures.
New research reveals why giving multiple doses of a promising type 1 diabetes treatment doesn't improve outcomes beyond a single course.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
Systematic uric acid monitoring and treatment achieved 64% better remission rates than waiting for symptoms to guide therapy.
Advanced photon-counting CT technology reveals arterial inflammation in giant cell arteritis with superior clarity.
A major review maps emerging immunotherapiesโfrom JAK inhibitors to microbiome interventionsโthat could transform care for celiac and food allergy patients.
A clinical case from Japan illustrates how cryoglobulinemia can drive membranoproliferative glomerulonephritis, a serious kidney complication.
Historical analysis reveals how colchicum has remained a cornerstone gout treatment for over 2,000 years of medical practice.
A Phase 4 trial tests whether simplifying HIV treatment to two drugs worsens hidden viral replication and immune dysfunction.
A major review outlines how targeted hematologic therapies are transforming outcomes in MGRS, a rare but serious cause of kidney injury.
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
Major meta-analysis reveals people with type 1 diabetes face nearly 3x higher depression risk, while celiac disease increases risk by 66%.
New research reveals how our body clock regulates immune cell function through DNA modifications, offering insights for health optimization.
New research reveals metformin can silence HIV and boost immune control, offering hope for treatment-free remission.
Review examines immunosuppressive drugs like cyclosporine and tacrolimus, highlighting new applications and safety management strategies.
